Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close
Neurocrine Biosciences Inc · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $161.00
+7.8% in 7d after detection
Post-detection moves
1h
—
1d
+1.7%
3d
+2.4%
7d
+7.8%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS